With stocks like St. Jude Medical, Boston Scientific, Medtronic (NYSE: MDT ) , and Johnson & Johnson (NYSE: JNJ ) so strong in 2013, Abbott Labs (NYSE: ABT )
has been tapped by many sell-side analysts as a catch-up pick for
2014. For the second straight quarter, though, Abbott has come in a
little shy of growth expectations. Although the excuse was reasonable
(the ongoing impact of Fonterra recalls on nutrition), there's not a lot
of tolerance in Abbott's valuation model for ongoing shortfalls.
Please read more here:
Wall Street Less Forgiving Toward Abbott Laboratories This Time
No comments:
Post a Comment